Ipratropium Steri-Neb

Ipratropium bromide nebuliser solution (Steri-Neb) is a short-acting muscarinic antagonist (SAMA) bronchodilator used to relieve acute and chronic bronchospasm associated with COPD and, in some circumstances, severe asthma. It is administered via a nebuliser and provides rapid airway smooth muscle relaxation by blocking muscarinic M3 receptors.

How Ipratropium Works

Ipratropium blocks the action of acetylcholine at parasympathetic nerve terminals in the bronchial smooth muscle. Normally, acetylcholine stimulates muscarinic receptors to cause bronchoconstriction; by blocking these receptors, ipratropium causes bronchodilation and reduces mucus secretion. Unlike beta-2 agonists such as salbutamol, ipratropium acts more slowly (peak effect at 30–90 minutes) but provides complementary and sometimes longer-lasting bronchodilation.

Clinical Applications

Ipratropium Steri-Neb is used in acute COPD exacerbations, often in combination with a nebulised short-acting beta-2 agonist (SABA) such as salbutamol. It is also used in acute severe asthma when additional bronchodilator therapy is needed beyond salbutamol alone. In hospital and emergency settings, the nebulised form is preferred for patients who cannot use handheld inhalers effectively.

How to Use Ipratropium Steri-Neb

Draw up the required dose from the unit-dose vial and place it into the nebuliser chamber. Attach the mask or mouthpiece, connect the tubing, and switch on the compressor. Breathe normally through the mouthpiece or mask until the nebuliser starts to sputter, indicating the dose is complete, which typically takes 10 to 15 minutes.

Dosing

For adults with COPD, the standard dose is 250 to 500 micrograms (one to two unit-dose vials), nebulised three to four times daily. For acute exacerbations in hospital, higher or more frequent doses may be used under medical supervision. In asthma (where used), 250 micrograms two to four times daily is typical. Always use the dose your doctor has prescribed.

Ipratropium Steri-Neb is a bronchodilator for regular symptom management — it is not a rapid-acting rescue inhaler for acute attacks. Keep a short-acting beta-agonist (such as salbutamol) available for acute breathlessness.

Ipratropium Steri-Neb is available as unit-dose vials of 250 mcg/mL in 1 mL and 2 mL volumes. The standard adult nebulised dose is 500 mcg (2 mL) three to four times daily for COPD maintenance or acute exacerbations. Doses may be given more frequently in acute settings under medical supervision.

Common Side Effects

• Dry mouth (the most common side effect, due to the anticholinergic mechanism)
• Cough during or after nebulisation
• Nausea or digestive discomfort
• Headache

Eye Precautions

If the aerosol accidentally contacts the eyes (particularly likely with a face mask), it can cause blurred vision, increased eye pressure (particularly dangerous in those with narrow-angle glaucoma), and eye pain. Always ensure the mask fits well against the face and direct the mist away from the eyes. If eye symptoms occur, seek prompt medical advice. Tell your doctor if you have a history of glaucoma or problems with urination before starting ipratropium.

Use with great caution in patients with narrow-angle glaucoma — ensure the nebuliser mask fits correctly to prevent mist entering the eyes. Use with caution in patients with benign prostatic hyperplasia or bladder outflow obstruction. Ipratropium is not for first-line use in acute asthma; salbutamol remains the primary bronchodilator. Avoid inadvertent ocular exposure. Not recommended as sole maintenance therapy for COPD; long-acting bronchodilators are preferred for regular use.

Contraindicated in patients with known hypersensitivity to ipratropium bromide, atropine, or related compounds, or to any excipient. Use in children under 6 months has not been established.